Logo Prima Biomed

Welcome to the Newsroom

11 December 2015

Prima BioMed progresses Japanese Collaboration

  • New Material Transfer Agreement (MTA) concluded with Yamaguchi University and NEC Corporation
  • Parties have combined a cancer vaccine with Prima’s IMP321 Antigen Presenting Cell (APC) activator
  • Pre-clinical work has shown that low dose IMP321 co-injected with a peptide vaccine is safe
  • Yamaguchi University intends to initiate clinical research in different cancer indications